Tirzepatide Side Effects: What Studies and FDA Data Show
Tirzepatide Side Effects: What Is Common, What Is Serious, and How Long They Last
Every number below comes from the FDA prescribing information and the SURMOUNT trials, not from forums. Here is what people on tirzepatide actually experienced, how often, and which symptoms mean you should call a doctor.
The most common tirzepatide side effects are digestive: nausea (25–29% vs 8% on placebo), diarrhea (19–23%), constipation (11–17%) and vomiting (8–13%). Most start during dose increases and fade over the following weeks. Serious problems such as pancreatitis or gallbladder disease are uncommon but need prompt medical attention.
What Are the Most Common Side Effects of Tirzepatide?
Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for weight management) slows how fast the stomach empties and acts on appetite centers in the brain. That is why its most frequent side effects involve the gut. In the two pooled placebo-controlled weight-loss trials behind the Zepbound label, 56% of people on any tirzepatide dose reported a digestive side effect, compared with 30% on placebo [1].
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Constipation | 5% | 17% | 14% | 11% |
| Vomiting | 2% | 8% | 11% | 13% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Indigestion (dyspepsia) | 4% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Allergic-type (hypersensitivity) reactions | 3% | 5% | 5% | 5% |
| Burping (eructation) | 1% | 4% | 5% | 5% |
| Hair loss | 1% | 5% | 4% | 5% |
| Acid reflux (GERD) | 2% | 4% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
| Gas, bloating | 2% | 3% | 3% | 4% |
| Low blood pressure | 0% | 1% | 1% | 2% |
Two things stand out. First, higher doses do not automatically mean more of every side effect: constipation was actually most common at 5 mg. Second, the large majority of people kept going. Only 4.8–6.7% stopped tirzepatide because of side effects, versus 3.4% on placebo [1].
How Long Do Tirzepatide Side Effects Last?
For most people, digestive side effects are a phase, not a permanent state. The FDA label states that most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. People who stopped because of side effects usually did so in the first few months, not later [1].
A practical way to think about it:
- First days after a new dose: nausea, fullness and loss of appetite are most noticeable.
- Following weeks at the same dose: symptoms usually ease as the body adapts.
- After reaching a stable maintenance dose: ongoing nausea is much less common. Constipation can linger longer than nausea for some people.
One reassuring finding: in a post hoc analysis of SURMOUNT-1, weight loss was similar whether or not people had digestive side effects [2]. Feeling sick is not what makes the drug work.
Why Do Side Effects Come Back After a Dose Increase?
Tirzepatide is started low and raised step by step precisely because the gut needs time to adjust. Each step up briefly restarts that adjustment, so nausea or diarrhea can reappear for a short time. Discontinuation for digestive side effects rose with dose: 1.9% at 5 mg, 3.3% at 10 mg and 4.3% at 15 mg, versus 0.5% on placebo [1]. This is why prescribers sometimes keep a patient on the same dose longer before moving up.
Advice clinicians commonly give for digestive symptoms includes eating smaller meals, stopping at the first sign of fullness, limiting greasy or very fatty food, and drinking enough fluids, especially with vomiting or diarrhea.
Does Tirzepatide Cause Hair Loss?
Hair loss was reported by about 5% of people on tirzepatide versus 1% on placebo [1]. The label links it to weight reduction itself. Rapid weight loss of any kind can trigger temporary shedding (telogen effluvium). It was far more common in women: 7.1% of women vs 0.5% of men on tirzepatide [1]. No one in the trials stopped tirzepatide because of hair loss [1].
Fatigue, Dizziness and "Sulfur Burps": The Quieter Side Effects
- Fatigue: 5–7% vs 3% on placebo (includes weakness, lethargy and malaise) [1]. Eating much less than usual is a common contributor.
- Burping: 4–5% vs 1% [1]. Slower stomach emptying keeps food in the stomach longer, which is behind the "sulfur burps" many people describe online.
- Dizziness and low blood pressure: dizziness 4–5% and hypotension 1–2% [1]. This matters more for people on blood-pressure medication, since their needs can change as weight drops.
- Heart rate: resting heart rate rose by an average of 1–3 beats per minute [1].
- Injection site reactions: redness, itching or bruising in 6–8% vs 2% [1].
Serious Side Effects: How Rare Are They?
These are the risks the FDA lists as warnings. They are uncommon, but they are the ones worth knowing by their symptoms.
| Risk | How often in trials | Warning signs |
|---|---|---|
| Severe digestive reactions | 1.7–3.1% vs 1.0% placebo | Vomiting or diarrhea you cannot keep up with. Not recommended in severe gastroparesis |
| Gallbladder disease | Gallstones 1.1% vs 1.0%; gallbladder inflammation 0.7% vs 0.2% | Pain in the upper right abdomen, fever, yellowing of skin or eyes |
| Acute pancreatitis | 0.2% vs 0.2% placebo in weight-loss trials | Severe, persistent abdominal pain that may spread to the back, with or without vomiting |
| Acute kidney injury | 0.5% vs 0.2% | Usually from dehydration after vomiting or diarrhea: little urine, dizziness, confusion |
| Severe allergic reaction | 0.1% vs none | Swelling of face, lips or throat, trouble breathing, widespread rash |
| Low blood sugar | 4.2% vs 1.3% in people with type 2 diabetes; 0.3% without diabetes | Shakiness, sweating, confusion. Higher risk with insulin or sulfonylureas |
| Diabetic eye complications | Reported in people with type 2 diabetes | Vision changes. People with diabetic retinopathy need eye monitoring |
| Aspiration during anesthesia | Rare post-marketing reports | Food can remain in the stomach despite fasting. Tell the surgical team you take tirzepatide |
Does Tirzepatide Cause Thyroid Cancer?
Tirzepatide carries the FDA's strongest warning, a boxed warning, because it caused thyroid C-cell tumors in rats. Whether this happens in humans is unknown [1]. Because of that uncertainty, tirzepatide must not be used by anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A lump in the neck, trouble swallowing, persistent hoarseness or shortness of breath should be checked by a doctor.
Does Tirzepatide Cause Depression or Suicidal Thoughts?
Current evidence says no. In January 2026 the FDA completed a review of 91 placebo-controlled trials with 107,910 patients and found no increased risk of suicidal thoughts or behavior, or of depression, anxiety or psychosis, with GLP-1 weight-loss drugs [3]. The agency asked manufacturers to remove the warning. The Zepbound label now lists the suicidal behavior and ideation warning as removed (02/2026) [1]. Anyone who feels persistently low should still talk to a doctor, since major weight and lifestyle change can affect mood for many reasons.
Does Tirzepatide Affect Birth Control?
Yes, it can affect birth control pills. Because tirzepatide slows stomach emptying, it can reduce how well oral contraceptives are absorbed. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase [1]. This interaction is easy to miss and is one of the most practical things to know.
Muscle Loss and "Ozempic Face"
Any large weight loss includes some lean tissue. In a body-composition substudy of SURMOUNT-1, roughly three-quarters of the weight lost was fat and one-quarter lean mass [4], a ratio similar to other forms of substantial weight loss. "Ozempic face" is not a medical diagnosis. It describes facial volume loss that follows rapid weight loss in general, not a unique drug effect. Adequate protein and resistance exercise are the usual recommendations to protect muscle during weight loss.
Tirzepatide vs Semaglutide: Which Has More Side Effects?
The only head-to-head trial, SURMOUNT-5 (751 adults, 72 weeks), found similar types of side effects with both drugs, mostly mild to moderate digestive effects during dose escalation. Fewer people stopped tirzepatide because of digestive problems: 2.7% vs 5.6% with semaglutide [5]. Injection site reactions, however, were more common with tirzepatide [5]. Tirzepatide also produced more weight loss: 20.2% vs 13.7%. For the full comparison, see our semaglutide evidence review and how tirzepatide works.
Are Mounjaro and Zepbound Side Effects the Same?
Yes, largely. Both contain the same molecule, and digestive effects dominate with both. The main practical difference is context. Mounjaro is prescribed for type 2 diabetes, often alongside insulin or sulfonylureas, which raises the risk of low blood sugar. Diabetic eye complications are also mainly a concern for people with diabetes.
Compounded and Unregulated Tirzepatide: Extra Risks
All the numbers in this article come from the FDA-approved product. Compounded or unregulated versions add risks the trials never measured: dosing mistakes with multi-dose vials, salt forms that were never tested in humans, and added ingredients. The FDA has received hundreds of adverse event reports tied to compounded tirzepatide, many involving dosing errors. Read more in Compounded Tirzepatide: What Researchers Should Know.
- Severe stomach pain that does not go away, with or without vomiting
- Vomiting or diarrhea that prevents you from keeping fluids down
- Pain in the upper right abdomen, fever, or yellow skin or eyes
- Swelling of the face, lips or throat, or trouble breathing
- A lump or swelling in the neck, trouble swallowing, or persistent hoarseness
- Very little urine, severe dizziness or confusion
- Sudden vision changes if you have diabetes
Also tell your surgeon or anesthesiologist that you take tirzepatide before any planned procedure.
Frequently Asked Questions
What is the most common side effect of tirzepatide?
Nausea. It affected 25–29% of people on tirzepatide in the main weight-loss trials, compared with 8% on placebo. Diarrhea (19–23%) was second.
Do tirzepatide side effects go away?
For most people, yes. The FDA label states that most nausea, vomiting and diarrhea happened during dose increases and decreased over time. Fewer than 7% of trial participants stopped because of side effects.
Does tirzepatide make you tired?
It can. Fatigue was reported by 5–7% of people on tirzepatide versus 3% on placebo. Eating much less than before often contributes.
Is hair loss from tirzepatide permanent?
Hair loss on tirzepatide is linked to rapid weight loss, which typically causes temporary shedding. It was reported by about 5% of people and was much more common in women. No trial participant stopped the drug because of it.
Can tirzepatide affect birth control pills?
Yes. It can reduce absorption of oral contraceptives. The label advises a non-oral method or an added barrier method for 4 weeks after starting and after each dose increase.
Does tirzepatide cause pancreatitis?
Pancreatitis is a listed warning, but in the weight-loss trials it occurred in 0.2% of people on tirzepatide and 0.2% on placebo. Severe, persistent abdominal pain should always be checked by a doctor.
Related Research
- Tirzepatide Research: How the Dual Agonist Works
- Tirzepatide News in 2026: Research, Regulation and Market
- The GLP-1 Non-Responder Problem
- Semaglutide Research: Trials, Heart and Kidney Outcomes
This article summarizes the FDA prescribing information and published clinical trials for educational purposes. It is not medical advice and does not replace a conversation with a licensed healthcare professional. Ordinary Peptides does not sell tirzepatide. Products offered on this site are for laboratory research use only and are not for human consumption.
Sources
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: Full Prescribing Information, revised 08/2026. uspl.lilly.com/zepbound/zepbound.html
- Eli Lilly Medical Information. How often were gastrointestinal adverse events reported in Zepbound clinical studies? medical.lilly.com
- U.S. FDA safety review of GLP-1 receptor agonists and suicidal ideation, January 2026. Reported by HealthDay, January 15, 2026. healthday.com
- Look M et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab, 2025;27:2720–2729. pubmed.ncbi.nlm.nih.gov/39996356
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM, 2025;393:26–36. nejm.org/doi/full/10.1056/NEJMoa2416394
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022;387:205–216. nejm.org/doi/full/10.1056/NEJMoa2206038